ACB
Price
$4.46
Change
+$0.08 (+1.83%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
238.86M
77 days until earnings call
OGI
Price
$1.03
Change
-$0.01 (-0.96%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
200.85M
Ad is loading...

ACB vs OGI

Header iconACB vs OGI Comparison
Open Charts ACB vs OGIBanner chart's image
Aurora Cannabis
Price$4.46
Change+$0.08 (+1.83%)
Volume$6.12K
Capitalization238.86M
Organigram Global
Price$1.03
Change-$0.01 (-0.96%)
Volume$8.56K
Capitalization200.85M
ACB vs OGI Comparison Chart
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. OGI commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and OGI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (ACB: $4.47 vs. OGI: $1.04)
Brand notoriety: ACB: Notable vs. OGI: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 21% vs. OGI: 65%
Market capitalization -- ACB: $238.86M vs. OGI: $200.85M
ACB [@Pharmaceuticals: Other] is valued at $238.86M. OGI’s [@Pharmaceuticals: Other] market capitalization is $200.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileOGI’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • OGI’s FA Score: 0 green, 5 red.
According to our system of comparison, ACB is a better buy in the long-term than OGI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while OGI’s TA Score has 4 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 4 bearish.
  • OGI’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, OGI is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а +1.36% price change this week, while OGI (@Pharmaceuticals: Other) price change was -2.80% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.71%. For the same industry, the average monthly price growth was -0.38%, and the average quarterly price growth was -8.58%.

Reported Earning Dates

ACB is expected to report earnings on Jun 19, 2025.

OGI is expected to report earnings on Nov 27, 2023.

Industries' Descriptions

@Pharmaceuticals: Other (-1.71% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($239M) has a higher market cap than OGI($201M). ACB YTD gains are higher at: 5.176 vs. OGI (-35.404). OGI has higher annual earnings (EBITDA): -195.74M vs. ACB (-1.64B). ACB has more cash in the bank: 149M vs. OGI (42.3M). OGI has less debt than ACB: OGI (136K) vs ACB (103M). ACB has higher revenues than OGI: ACB (212M) vs OGI (161M).
ACBOGIACB / OGI
Capitalization239M201M119%
EBITDA-1.64B-195.74M836%
Gain YTD5.176-35.404-15%
P/E RatioN/AN/A-
Revenue212M161M132%
Total Cash149M42.3M352%
Total Debt103M136K75,735%
FUNDAMENTALS RATINGS
ACB vs OGI: Fundamental Ratings
ACB
OGI
OUTLOOK RATING
1..100
659
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9094
PRICE GROWTH RATING
1..100
6290
P/E GROWTH RATING
1..100
8296
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGI's Valuation (52) in the null industry is in the same range as ACB (56) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to ACB’s over the last 12 months.

OGI's Profit vs Risk Rating (100) in the null industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that OGI’s stock grew similarly to ACB’s over the last 12 months.

ACB's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as OGI (94) in the null industry. This means that ACB’s stock grew similarly to OGI’s over the last 12 months.

ACB's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as OGI (90) in the null industry. This means that ACB’s stock grew similarly to OGI’s over the last 12 months.

ACB's P/E Growth Rating (82) in the Pharmaceuticals Other industry is in the same range as OGI (96) in the null industry. This means that ACB’s stock grew similarly to OGI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBOGI
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 14 days ago
77%
Bullish Trend 17 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AGRFX100.72N/A
N/A
AB Growth A
ATHAX18.14N/A
N/A
American Century Heritage A
BLRAX11.22N/A
N/A
Brookfield Global Listed Real Estate A
FIQDX8.68N/A
N/A
Fidelity Advisor Strategic Real Ret Z
APAYX10.98N/A
N/A
Integrity Dividend Summit A